

DAFTAR PUSTAKA

- Abu Farha, R., Saleh, A. and AbuRuz, S. (2017) "The impact of drug related problems on health-related quality of life among hypertensive patients in Jordan," *Pharmacy Practice*, 15(3), pp. 995–995. doi:10.18549/PharmPract.2017.03.995.
- Altyar, A.E. et al. (2020) "Evaluating Pharmacy Practice in Hospital Settings in Jeddah City, Saudi Arabia: Prescribing and Transcribing—2018," *Hospital Pharmacy*, 55(5), pp. 306–313. doi:10.1177/0018578719844707.
- Barbot, M., Ceccato, F. and Scaroni, C. (2019) "The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome," *Frontiers in Endocrinology*, 10. doi:10.3389/fendo.2019.00321.
- Barreras, A. and Gurk-Turner, C. (2003) "Angiotensin li Receptor Blockers," *Baylor University Medical Center Proceedings*, 16(1), pp. 123–126. doi:10.1080/08998280.2003.11927893.
- Bekele, F. et al. (2021) "Drug-related problems among patients with infectious disease admitted to medical wards of Wollega University Referral Hospital: Prospective observational study," *SAGE Open Medicine*, 9, p. 205031212198962. doi:10.1177/2050312121989625.
- Bromfield, S.G. et al. (2017) "Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With Hypertension," *Hypertension*, 70(2), pp. 259–266. doi:10.1161/HYPERTENSIONAHA.116.09390.
- Carey, R.M. et al. (2018) "Prevention and Control of Hypertension," *Journal of the American College of Cardiology*, 72(11), pp. 1278–1293. doi:10.1016/j.jacc.2018.07.008.
- Chaturvedi, V.P., Mathur, A.G. and Anand, A.C. (2012) "Rational drug use – As common as common sense?," *Medical Journal Armed Forces India*, 68(3), pp. 206–208. doi:10.1016/j.mjafi.2012.04.002.
- Choudhry, N.K. et al. (2022) "Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association," *Hypertension*, 79(1). doi:10.1161/HYP.000000000000203.
- Cipolle, R. J., Strand, L. M., & Morley, P. C. (2012). *The Care Plan. In Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services* (3rd ed.). McGraw Hill Medical.
- Cuzzo, B., Padala, S.A. and Lappin, S.L. (2020) "Physiology, Vasopressin," *StatPearls* [Preprint].
- Depkes RI. (2009). Undang-Undang Nomor 36 Tahun 2009 tentang Kesehatan. indonesia




- Ecobici, M. and Stoicescu, C. (2017) "Arterial Stiffness and Hypertension - Which Comes First?," *Maedica*, 12(3), pp. 184–190.
- Elliott, W.J. and Ram, C.V.S. (2011) "Calcium Channel Blockers," *The Journal of Clinical Hypertension*, 13(9), pp. 687–689. doi:10.1111/j.1751-7176.2011.00513.x.
- Ellis, D. and Miyashita (2011) "Primary hypertension and special aspects of hypertension in older children and adolescents," *Adolescent Health, Medicine and Therapeutics*, p. 45. doi:10.2147/AHMT.S11715.
- Ellison, D.H. (2019) "Clinical Pharmacology in Diuretic Use," *Clinical Journal of the American Society of Nephrology*, 14(8), pp. 1248–1257. doi:10.2215/CJN.09630818.
- Everett, B. and Zajacova, A. (2015) "Gender Differences in Hypertension and Hypertension Awareness Among Young Adults," *Biodemography and Social Biology*, 61(1), pp. 1–17. doi:10.1080/19485565.2014.929488.
- Fares, H. et al. (2016) "Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes.," *Open heart*, 3(2), p. e000473. doi:10.1136/openhrt-2016-000473.
- Farzam, K. and Jan, A. (2021) "Beta Blockers," *Drugs in Sport, Seventh Edition*, pp. 307–315.
- Fathnin, F.H., Yuniastuti, A. and Kasmini, O.W. (2020) "The Relation of Drug Amount, Comorbidity, Blood Pressure, and Residential Area to Drug-Related-Problems of Hypertension Patients," *Public Health Perspectives Journal Fildza Huwaina Fathnin*, 5(3), pp. 2020–178. Available at: <http://journal.unnes.ac.id/sju/index.php/phpj>.
- Garin, N. et al. (2021) "Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions," *Scientific Reports*, 11(1), p. 883. doi:10.1038/s41598-020-80560-2.
- Guerrero-García, C. and Rubio-Guerra, F. (2018) "Combination therapy in the treatment of hypertension," *Drugs in Context*, 7, pp. 1–9. doi:10.7573/dic.212531.
- Guichard, J.L. et al. (2013) "Aldosterone receptor antagonists: current perspectives and therapies," *Vascular Health and Risk Management*, 9, pp. 321–331. doi:10.2147/VHRM.S33759.
- Harahap, O.H., Badiran, M. and Asriwati (2020) "Analisis Hubungan Peresepan dengan Penggunaan Obat Rasional di Puskesmas Bestari Kecamatan Medan Petisah," *Excellent Midwifery Journal*, 3 No.1, pp. 12–25.
- Hegde, S. and Aeddula, N.R. (2021) "Secondary Hypertension," *StatPearls [Preprint]*.

- Herman, L.L. et al. (2021) "Angiotensin Converting Enzyme Inhibitors (ACEI)."
- Herman, L.L. et al. (2022) Angiotensin Converting Enzyme Inhibitors (ACEI).
- Hernandez-Vila, E. (2015) "A Review of the JNC 8 Blood Pressure Guideline," *Texas Heart Institute Journal*, 42(3), pp. 226–228. doi:10.14503/THIJ-15-5067.
- Hough, A. et al. (2019) 'Hypertension', in J.T. DiPiro et al. (eds) *Pharmacotherapy Principles & Practice*. McGraw Hill.
- Huang, Q. et al. (2019) "A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension," *The Journal of Clinical Hypertension*, 21(5), pp. 648–657. doi:10.1111/jch.13543.
- Iqbal, A.M. and Jamal, S.F. (2021) "Essential Hypertension," *xPharm: The Comprehensive Pharmacology Reference*, pp. 1–6.
- Juwita, R. et al. (2015) Peran Apoteker dalam Mencegah Drug Related Problems pada Pasien Stroke yang Dirawat Inap, *Artikel Penelitian Neurna*.
- Kementerian Kesehatan RI (2011) "Modul Penggunaan Obat Rasional Dalam Praktek," *Modul Penggunaan Obat Rasional*, pp. 3–4.
- Kementerian Kesehatan RI (2019) Laporan Nasional Riskesdas 2018, Badan Penelitian dan Pengembangan Kesehatan. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
- Kerr, J.L. (2019) 'Hypertension', in S. Sutton (ed.) *McGrawHill's NAPLEX® Review Guide*. McGrawHill.
- Khalil, H. and Zeltser, R. (2021) "Antihypertensive Medications," *Southern Medical Journal*, 77(5), pp. 621–630.
- Kim, H.-J. et al. (2016) "Medication Adherence and the Occurrence of Complications in Patients with Newly Diagnosed Hypertension," *Korean Circulation Journal*, 46(3), p. 384. doi:10.4070/kcj.2016.46.3.384.
- MacLaughlin, E.J. and Saseen, J.J. (2020) "Hypertension," in DiPiro, J.T. et al. (eds) *Pharmacotherapy: a Pathophysiology Approach 11th Edition*. 11th edn. New York: Mc Graw Hill, pp. 273–359.
- Mahmood, S. et al. (2021) "Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis," *International Journal of Clinical Pharmacy*, 43(3), pp. 486–501. doi:10.1007/s11096-021-01236-z.

- Mayet, J. and Hughes, A. (2003) "Cardiac and vascular pathophysiology in hypertension," *Heart*, 89(9), pp. 1104–1109. doi:10.1136/heart.89.9.1104.
- McEvoy, J.W. et al. (2020) "Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes," *JAMA*, 323(4), p. 329. doi:10.1001/jama.2019.21402.
- McKeever, R.G. and Hamilton, R.J. (2022) Calcium Channel Blockers.
- Ni, X.-F. et al. (2021) "Drug-Related Problems of Patients in Primary Health Care Institutions: A Systematic Review," *Frontiers in Pharmacology*, 12. doi:10.3389/fphar.2021.698907.
- Oparil, S. et al. (2018) "Hypertension," *Nature Reviews Disease Primers*, 4(1), p. 18014. doi:10.1038/nrdp.2018.14.
- Parker, J.D. et al. (2020) "Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease," *Scientific Reports*, 10(1), p. 565. doi:10.1038/s41598-019-56890-1.
- Princewel, F. et al. (2019) "Prevalence and risk factors associated with hypertension among adults in a rural setting: the case of Ombe, Cameroon," *Pan African Medical Journal*, 34. doi:10.11604/pamj.2019.34.147.17518.
- Rodziewicz, T.L., Houseman, B. and Hipskind, J.E. (2021) Medical Error Reduction and Prevention, StatPearls.
- Sabbatini, A.R. and Kararigas, G. (2020) "Estrogen-related mechanisms in sex differences of hypertension and target organ damage," *Biology of Sex Differences*, 11(1), p. 31. doi:10.1186/s13293-020-00306-7.
- Sanii, Y. et al. (2016) "Role of pharmacist counseling in pharmacotherapy quality improvement," *Journal of Research in Pharmacy Practice*, 5(2), p. 132. doi:10.4103/2279-042X.179580.
- Shrout, T., Rudy, D.W. and Piascik, M.T. (2017) "Hypertension update, JNC8 and beyond," *Current Opinion in Pharmacology*, 33, pp. 41–46. doi:10.1016/j.coph.2017.03.004.
- Shukuri, A., Tewelde, T. and Shaweno, T. (2019) "Prevalence of old age hypertension and associated factors among older adults in rural Ethiopia," *Integrated Blood Pressure Control*, Volume 12, pp. 23–31. doi:10.2147/IBPC.S212821.
- Smith, D.K., Lennon, R.P. and Carlsgaard, P.B. (2020) "Managing Hypertension Using Combination Therapy.," *American family physician*, 101(6), pp. 341–349.

- Song, J.-J. et al. (2020) "Gender Differences in Hypertension," *Journal of Cardiovascular Translational Research*, 13(1), pp. 47–54. doi:10.1007/s12265-019-09888-z.
- Tan, J.L. and Thakur, K. (2021) "Systolic Hypertension," StatPearls [Preprint].
- Tariq, R.A. et al. (2021) "Medication Dispensing Errors And Prevention," StatPearls [Preprint].
- Tuloli, T.S., Pakaya, M.S. and Pratiwi, S.D. (2021) "Identifikasi Drug Related Problems (DRPs) Pasien Hipertensi di RS Multazam Kota Gorontalo," *Indonesian Journal of Pharmaceutical Education (e-Journal)*, 1(1), pp. 2775–3670. doi:10.22487/ijpe.v1i1.9945.
- Wang, J. et al. (2020) "Mask use during COVID-19: A risk adjusted strategy," *Environmental Pollution*, 266(January), p. 115099. doi:10.1016/j.envpol.2020.115099.
- Weeda, E.R. et al. (2016) "Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis," *International Journal of Cardiology*, 216, pp. 104–109. doi:10.1016/j.ijcard.2016.04.082.
- WHO (2021) Hypertension. Available at: https://www.who.int/health-topics/hypertension#tab=tab_1 (Accessed: September 11, 2021).
- Woodford, H.J. (2020) "Calcium Channel Blockers Co-prescribed with Loop Diuretics: A Potential Marker of Poor Prescribing?," *Drugs & Aging*, 37(2), pp. 77–81. doi:10.1007/s40266-019-00730-4.
- Xanthakis, V. and Vasan, R.S. (2013) "Aldosterone and the Risk of Hypertension," *Current Hypertension Reports*, 15(2), pp. 102–107. doi:10.1007/s11906-013-0330-y.
- Zhou, S. et al. (2018) "Analyzing Medication Error Reports in Clinical Settings: An Automated Pipeline Approach.," *AMIA ... Annual Symposium proceedings. AMIA Symposium*, 2018, pp. 1611–1620.

Lampiran 1. Surat Izin Penelitian

	<p>KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS FARMASI Jalan Perintis Kemerdekaan Km.10, Makassar 90245 Telepon (0411) 586200, 589895 Faximili (0411) 585188 Laman unhas.ac.id</p>
Nomor : 1837/UN4.17/PT.01.04/2022	27 Juni 2022
Perihal : Permohonan Izin Penelitian	
Kepada Yth. Kepala Puskesmas Rembon Kecamatan Malimbong Balepe Tana Toraja	
Dengan hormat, sehubungan dengan pelaksanaan penelitian mahasiswa Fakultas Farmasi Universitas Hasanuddin, yaitu :	
Nama	: Katherine Maria Pusparini Buli
NIM	: N011181524
Program Studi	: S1 Farmasi
Kami mohon bantuan, kiranya mahasiswa yang bersangkutan di atas dapat diizinkan melakukan penelitian di Puskesmas Rembon Kecamatan Malimbong Balepe Tana Toraja dalam rangka penyusunan skripsi dengan judul "Evaluasi Penggunaan Terapi Antihipertensi pada Pasien Rawat Jalan di Puskesmas Rembon Kecamatan Malimbong Balepe, Tana Toraja"	
Demikian permohonan ini, atas perhatian dan bantuan disampaikan terima kasih.	
	<p>Dekan</p>  Prof. Subehan, M.Pharm., Sc., Ph.D., Apt. NIP. 197509252001121002
Tembusan :	
1. Wakil Dekan Bidang Akademik, Riset dan Inovasi;	
2. Ketua Gugus Penjaminan Mutu;	
3. Kabag. Tata Usaha;	
Arsip.	
	

Lampiran 2. Sertifikat *Ethical clearance*



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed,PhD., SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 461/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 25 Agustus 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22080424		No Sponsor	
Peneliti Utama	Katherine M Pusparini Buli		Sponsor	
Judul Peneliti	Evaluasi Penggunaan Terapi Antihipertensi pada Pasien Rawat Jalan di Puskesmas Rembon Kecamatan Malimbong Balepe Tana Toraja			
No Versi Protokol	1	Tanggal Versi	4 Agustus 2022	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	Puskesmas Rembon Kecamatan Malimbong Balepe Tana Toraja			
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	25 Agustus 2022 sampai 25 Agustus 2023	
Frekuensi review lanjutan				
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 3. Lembar Hasil Penelitian

No	Inisial	JK	Usia	Riwayat penyakit lain	Riwayat penggunaan obat (bulan sebelumnya)		Tgl Periksa	TD	Keluhan	Nama obat R/	pill count	Penyebab DRPS										
					Nama obat	dosis						Indikasi tanpa obat	Obat tanpa indikasi	Obat salah	Dosis obat kurang	Reaksi obat merugikan	Dosis obat lebih	kepatuhan				
1	M	L	64		Amlodipin 5 mg	1x1	10/04/21	160/90		Amlodipin 5 mg	100											
					Amlodipin 5 mg	1x1	21/4/2021	150/90		Amlodipin 5 mg												
					Amlodipin 5 mg	1x1	25/5/2021	140/90		Amlodipin 5 mg												
					Amlodipin 10 mg	1x1	03/06/21	160/190		Amlodipin 10 mg								X	X	X	X	X
					Amlodipin 5 mg	1x1	03/08/21	230/130		Amlodipin 10 mg												
					Amlodipin 5 mg	1x1	31/08/21	136/84		Amlodipin 5 mg											OK6	
2	DB	P		Asam urat Asam urat	Amlodipin 5 mg	1x1	04/05/21	160/90		Amlodipin 5 mg	100											
					Amlodipin 5 mg	1x1	04/06/21	150/80		Amlodipin 5 mg, Allopurinol, Vitamin B6												
					Amlodipin 5 mg, Allopurinol, Vitamin B6	1x1	02/07/21	160/80		Amlodipin 5 mg, Allopurinol								X	X	X	X	X
					Amlodipin 5 mg, Allopurinol	1x1	03/08/21	160/80		Amlodipin 5 mg												
					Amlodipin 5 mg	1x1	30/8/2021	154/86		Amlodipin 5 mg, Allopurinol, Simvastatin											OK6	
3	HS	P			Amlodipin 5 mg	1x1	07/05/21	150/100		Amlodipin 5 mg, Ibuprofen, Vitamin B1	100											
							31/08/21	140/90		Amlodipin 5 mg Amlodipin 5 mg, Omeprazole,								X	X	X	X	X

					Amlodipin 5 mg	1x1	29/2/2021	130/90		Amlodipin 5 mg								KP1
10	ML	L	61		Amlodipin 5 mg		13/9/2021	160/80		Amlodipin 5 mg	100	X	X	X	X	X	X	
11	PB	L			Amlodipin 5 mg	1x1	25/1/2019	160/100		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	06/02/19	140/100		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	19/2/2019	130/90										
12	E	P	70		Amlodipin 5 mg	1x1	07/03/20	180/90		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	09/06/21	170/80		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	02/07/21	180/80		Amlodipin 5 mg					OK6			
13	TS	P			Amlodipin 5 mg	1x1	31/1/2020	150/90		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	26/3/2020	140/90		Amlodipin 5 mg	80							
					Amlodipin 5 mg	1x1	08/04/21	160/90		Amlodipin 5 mg								KP1
14	M	P					08/02/21	160/100		Amlodipin 5 mg	100							
15	HS	P	54		Amlodipin 5 mg	1x1	02/05/21	150/90		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	03/05/21	110/60		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	04/05/21	200/100		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	28/5/2021	140/80		Amlodipin 10 mg	100							
					Amlodipin 10 mg	1x1	08/06/21	130/80		Amlodipin 5 mg					OK7			
16	JS	L	66		Amlodipin 5 mg	1x1	31/1/2019	120/20		Amlodipin 5 mg								
17	MR	P			Amlodipin 5 mg	1x1	04/04/20	180/100		Amlodipin 5 mg					OK6			
					Amlodipin 5 mg	1x1	03/07/21	200/100		Amlodipin 10 mg	100							
					Amlodipin 10 mg	1x1	31/7/2021	160/100		Amlodipin 5 mg								

					<u>Amlodipin 5 mg</u>	<u>1x1</u>	<u>20/8/2021</u>	<u>170/100</u>		<u>Amlodipin 5 mg</u>								
18	JTL	L	57		<u>Amlodipin 5 mg</u>	<u>1x1</u>	<u>21/12/2020</u>	<u>140/80</u>		<u>Amlodipin 5 mg</u>								
					Amlodipin 5 mg	1x1	23/6/21	140/90		Amlodipin 5 mg								
					<u>Amlodipin 5 mg</u>	<u>1x1</u>	<u>28/8/2021</u>	<u>140/90</u>		<u>Amlodipin 5 mg</u>								
19	YRL	P	68		Amlodipin 5 mg	1x1	08/10/17	140/100		Nifedipin								
					Nifedipin	1x1	13/11/2017	140/100		Amlodipin								
20	YRT	P	51		Amlodipin 5 mg	1x1	08/06/21	170/110		Amlodipin 5 mg	75							KP1
21	AR	L	51		Amlodipin	1x1	08/09/21	140/77		Livron	100							
22	AK	P	67				08/06/21	200/100		Amlodipin 5 mg	100			OS2				
23	L	L	72		Amlodipin 5 mg, ciprofloxacin	1x1	15/7/2020	130/70		Amlodipin 5 mg	100							
24	PP	P	78		Amlodipin 5 mg	1x1	26/08/21	170/70		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	28/08/21	160/80		Amlodipin 5 mg								
25	AK	P	59		Nifedipin	1x1	04/04/20	150/80		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	19/7/2021	140/80		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	18/8/2021	150/90		Amlodipin 5 mg				OK6				
26	YL	L	52		Amlodipin 10 mg	1x1	23/06/21	160/90		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	17/5/2021	160/100		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	08/02/21	130/90		Amlodipin 5 mg								
27	LM	L	63		Amlodipin 5 mg	1x1	08/06/21	180/90		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	08/12/21	150/90		Amlodipin 5 mg								
28	WS	L	75		Amlodipin 5 mg	1x1	13/1/2021	160/90		Amlodipin 5 mg								

					Amlodipin 5 mg	1x1	22/6/2021	180/110		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	21/7/2021	140/90		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	20/8/2021	130/80		Amlodipin 5 mg								
29	PS	L	76		Amlodipin 5 mg	1x1	23/5/2018	130/90		Amlodipin 5 mg	100							
30	P	L			Amlodipin 100 mg	1x1	18/8/2020	170/70		Amlodipin 10 mg								
					Amlodipin 10 mg	1x1	21/1/2021	203/83		Amlodipin 10 mg	100							
					Amlodipin 10 mg	1x1	11/02/21	180/90		Amlodipin 10 mg								
					Amlodipin 10 mg	1x1	15/7/2021	160/70		Amlodipin 10 mg								
31	JP	L	79		Captopril	1x1	29/11/2014	150/100		Captopril								
					Captopril	1x1	10/12/14	150/100		Amlodipin	100							
					Amlodipin	1x1	19/12/2014	120/110		Amlodipin								
32	PP	L	42		Amlodipin 5 mg	1x1	26/11/2020	138/90		Amlodipin 5 mg	100							
33	R	L	31		Nifedipin	1x1	15/5/2021	150/90		Nifedipin								
					Nifedipin	1x1	14/6/2021	150/100		Nifedipin	100							
					Nifedipin	1x1	14/7/2021	150/100		Nifedipin					OK1			
34	MPP	P	53		Amlodipin 5 mg	1x1	28/5/2021	120/80		amlodipin 5 mg								
					Amlodipin 5 mg	1x1	16/7/2021	120/80		amlodipin 5 mg	100							
35	AD	P	44		Amlodipin 5 mg	1x1	08/10/21	190/130		Amlodipin 5 mg	100							
36	HR	L	65		Amlodipin	1x1	25/3/2021	170/90		Amlodipin								
					Amlodipin	1x1	24/4/2021	139/95		Amlodipin	100							
37	BL	L	78		Amlodipin 5 mg	1x1	20/8/2021	140/83		Amlodipin 5 mg	100							
38	S	P	58				08/06/21	190/110		Amlodipin 5 mg	100						OK1	
39	L	P	61		Nifedipin	1x1	12/03/21	140/60		Nifedipin								

					Nifedipin	1x1	27/4/2021	160/90		Amlodipin	100				OK7			
40	BL	L	68		Amlodipin 5 mg	1x1	28/12/2020	136/87		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	25/2/2021	130/80		Amlodipin 10 mg	100							
41	DL	P	56				08/07/21	200/110		Amlodipin 5 mg	100				OK6			
42	MB	P	73		Amlodipin 5 mg	1x1	03/11/21	150/90		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	31/5/2021	160/100		Amlodipin 5 mg								
					Amlodipin 5 mg	1x1	26/6/2021	120/70		Amlodipin 5 mg								
43	DT	L	51		Amlodipin 5 mg	1x1	17/6/2021	130/90		Amlodipin 5 mg	100							
44	PP	P	51	Asam urat	Amlodipin 10 mg	1x1	20/8/2021	120/90		Amlodipin 10 mg, Allopurinol	100							
45	AP	L			Amlodipin 10 mg	1x1	06/11/21	180/110		Amlodipin 10 mg	100							
					Amlodipin 5 mg	1x1				Amlodipin 5 mg								
46	DP	L	62		Amlodipin 10 mg	1x1	17/5/2021	200/110		Amlodipin 10 mg								
					Amlodipin 10 mg	1x1	12/06/21	170/90		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	02/07/21	110/100		Amlodipin 5 mg								
47	BL	P	53		Amlodipin 5 mg	1x1	22/4/2021	180/100		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	09/06/21	170/90		Amlodipin 10 mg								
48	S	L	81		Amlodipin 5 mg	1x1	19/6/2021	160/70		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1				Amlodipin 5 mg								
49	L	L			Amlodipin 5 mg	1x1	30/6/2021	120/70		Amlodipin 5 mg	100							
					Amlodipin 5 mg	1x1	05/08/21	110/70		Amlodipin 5 mg								
50	LL	P	47		Amlodipin 5 mg	1x1	13/12/2019	130/80		Amlodipin								

					Amlodipin 5 mg	1x1	15/06/20	150/90		Amlodipin 5 mg	100						
					Amlodipin 5 mg	1x1	05/10/20	150/90		Amlodipin 5 mg							
					<u>Amlodipin 5 mg</u>	1x1	<u>06/11/20</u>	<u>140/90</u>		<u>Amlodipin 5 mg</u>							
51	YT	L	69		Amlodipin 5 mg, Furosemid	1x1 (1-0-0)	24/6/2021	160/100		Amlodipin, Furosemid	100						
							<u>03/07/21</u>	<u>160/90</u>		Amlodipin, Furosemid							
52	YT	L	71		Amlodipin 5 mg		24/6/2021	140/90		Amlodipin 5 mg	100						
					Amlodipin 5 mg	1x1	25/8/2021	140/90		Amlodipin 5 mg							